Navigation Links
Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
Date:5/13/2013

NEW YORK, May 13, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCBB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced that the U.S. Patent and Trademark Office (USPTO) has allowed a key patent application in the Company's portfolio.  The patent application "Alpha Emitting Constructs and Uses Thereof" is licensed by Actinium Pharmaceuticals from Memorial Sloan Kettering Cancer Center (MSKCC). 

The application covers treatment of metastatic solid cancers by targeting either cancer cells directly or blood vessels that provide for their growth with appropriate carriers of alpha emitting isotopes actinium 225 and bismuth 213.  This technology allows Actinium Pharmaceuticals to expand use of its platform beyond blood borne and bone marrow located cancers, thus potentially offering broad categories of severely ill patients an efficacious therapy with a safety profile that could allow treatment of such patients.  The patent is expected to issue in the next few months. Actinium Pharmaceuticals retains an exclusive license to use, develop, and commercialize this patent.

Dragan Cicic , MD, CMO of Actinium Pharmaceuticals, said: "This decision is an important step towards our goal of expanding the use of our technology to address the vast unmet medical need area of metastatic cancers in older patients.  We have the potential to not only improve efficacy of cancer treatment but also enable it in many patients too sick to withstand the rigors of currently available therapies."

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc.  is a New York, NY based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

For more information:

Visit our web site www.actiniumpharmaceuticals.com or Contact:

Segio Traversa , CEO
Actinium Pharmaceuticals Inc.
E-mail: straversa@actiniumpharmaceuticals.com

Media:
Dennis S. Dobson Jr. , 203-258-0159
Email: dsdobson@optonline.com 
www.dobsonmediagroup.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
2. Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
3. Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
4. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
5. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
6. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
7. Actinium Pharmaceuticals Announces New Round of Financing
8. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
9. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
10. Actinium Pharmaceuticals Stockholders Vote to Approve Fundraising and Public Listing
11. Actinium Pharmaceuticals Strengthens Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016 ... Education in Clinical Neurophysiology  Elsevier , ... products and services, today announced the launch of ... open access journal that focuses on clinical practice issues ... case reports, clinical series, normal values and didactic reviews. ...
(Date:5/23/2016)... According to a new ... Product (Wheelchair, Scooters, Medical Beds, Bathroom Safety, Mechanical, ... Wound), Accessories (Lifting, Transfer) & by End User ... MarketsandMarkets, the patient handling equipment market is expected ... a CAGR of 10.5% during the forecast period ...
(Date:5/23/2016)... York , May 23, 2016 ... report titled, " Exocrine Pancreatic Insufficiency Market - Global ... - 2023 ." According to the report, the exocrine ... CAGR of 8.3% from 2015 to 2023 to reach ... (EPI) is a condition characterized by the deficiency of ...
Breaking Medicine Technology:
(Date:5/26/2016)... , ... May 26, 2016 , ... May 2016 – ... so central to popular cosmetic improvement efforts. Record numbers of clients now ask about ... prominent or pouty, says Kally Papantoniou, MD, of Advanced Dermatology P.C. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... In 1980, Bill Howe opened AM/PM Sewer and ... community. His vision to grow the company was built on a simple mission of ... level of training and customer service. Over 35 years later, Bill Howe remains one ...
(Date:5/26/2016)... ... May 26, 2016 , ... Women’s athletic ... host their second pop-up shop for three consecutive weekends. The pop-up shop is ... Santa Barbara community, a community full of women who appreciate the most premium ...
(Date:5/25/2016)... ... May 26, 2016 , ... The 12th session of the Silicon Valley BioTalks ... in Palo Alto, CA. This Bay Area biotech event will focus on “Setting Up ... from the pharmaceutical company Hallux, biopharma Apexigen, Contract Research Organization (CRO) Experien Group, and ...
(Date:5/25/2016)... ... , ... Furthering its position as the industry leader in drug education and ... (Drug Free Sport®) is excited to expand on details of its “Sport Exchange Summit, ... in Kansas City, MO, will gather sports industry professionals to examine, address and challenge ...
Breaking Medicine News(10 mins):